Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)

Trial Profile

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs IMR 687 (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Sponsors Imara Inc
  • Most Recent Events

    • 11 Oct 2018 According to an Imara Inc media release, a review of this trial will be presented at the Sickle Cell Disease Association of America's (SCDAA) 46th Annual National Convention.
    • 13 Feb 2018 According to an Imara media release, first patient has been dosed in this study.
    • 09 Jan 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top